Skip to main content
Midas Edge

CAPRICOR THERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Mar 17, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 17, 2026

CAPR$8.87-9.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE PERIOD FROM DECEMBER 31, 2023 THROUGH DECEMBER 31, 2025

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · OTHER · ​ · ​ · ​ · ​ · TOTAL
​ · ​ · COMMON STOCK · ​ · ADDITIONAL PAID- · ​ · COMPREHENSIVE · ​ · ACCUMULATED · ​ · STOCKHOLDERS'
​ · ​ ​ ​ · SHARES · ​ ​ ​ · AMOUNT · ​ ​ ​ · IN CAPITAL · ​ ​ ​ · INCOME · ​ ​ ​ · DEFICIT · ​ ​ ​ · EQUITY
​​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​​
Balance at December 31, 202331,148,320​$31,148​$181,701,859​$235,813​$(159,367,353)​$22,601,467
​​​​​​​​​​​​​​​​​​
Issuance of common stock, net of fees14,124,536​14,125​152,307,451​—​—​152,321,576
​​​​​​​​​​​​​​​​​​
Exercise of common warrants​105,782​​106​​144,288​​—​—​​144,394
​​​​​​​​​​​​​​​​​​
Stock-based compensation—​—​9,765,164​—​—​9,765,164
​​​​​​​​​​​​​​​​​​
Stock options exercised203,650​​203​​305,576​—​—​305,779
​​​​​​​​​​​​​​​​​​
Unrealized gain on marketable securities—​—​—​791,142​—​791,142
​​​​​​​​​​​​​​​​​​
Net loss—​—​—​—​(40,467,186)​(40,467,186)
​​​​​​​​​​​​​​​​​​
Balance at December 31, 202445,582,288​$45,582​$344,224,338​$1,026,955​$(199,834,539)​$145,462,336
​​​​​​​​​​​​​​​​​​
Issuance of common stock, net of fees9,582,307​9,582​237,024,356​—​—​237,033,938
​​​​​​​​​​​​​​​​​​
Exercise of common warrants​1,589,699​​1,590​​9,059,694​​—​—​9,061,284
​​​​​​​​​​​​​​​​​​
Stock-based compensation—​—​16,967,799​—​—​16,967,799
​​​​​​​​​​​​​​​​​​
Vesting of restricted stock awards​17,210​​17​​257,444​​—​​—​​257,461
​​​​​​​​​​​​​​​​​​
Stock options exercised​599,405​​600​​2,796,474​​—​​—​​2,797,074
​​​​​​​​​​​​​​​​​​
Unrealized loss on marketable securities​—​​—​​—​​(743,801)​​—​​(743,801)
​​​​​​​​​​​​​​​​​​
Net loss—​—​—​—​(105,043,946)​(105,043,946)
​​​​​​​​​​​​​​​​​​
Balance at December 31, 202557,370,909​$57,371​$610,330,105​$283,154​$(304,878,485)​$305,792,145
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.